- Home
- MNMD vs RXST Comparison
MNMD vs RXST Comparison
Compare MNMD & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- RXST
- Stock Information
- Founded
- MNMD 2019
- RXST 1997
- Country
- MNMD United States
- RXST United States
- Employees
- MNMD N/A
- RXST N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- RXST Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- MNMD Health Care
- RXST Health Care
- Exchange
- MNMD Nasdaq
- RXST Nasdaq
- Market Cap
- MNMD 509.2M
- RXST 553.1M
- IPO Year
- MNMD N/A
- RXST 2021
- Fundamental
- Price
- MNMD $7.17
- RXST $13.05
- Analyst Decision
- MNMD Strong Buy
- RXST Buy
- Analyst Count
- MNMD 7
- RXST 10
- Target Price
- MNMD $26.29
- RXST $39.30
- AVG Volume (30 Days)
- MNMD 1.2M
- RXST 654.3K
- Earning Date
- MNMD 08-12-2025
- RXST 08-04-2025
- Dividend Yield
- MNMD N/A
- RXST N/A
- EPS Growth
- MNMD N/A
- RXST N/A
- EPS
- MNMD N/A
- RXST N/A
- Revenue
- MNMD N/A
- RXST $148,310,000.00
- Revenue This Year
- MNMD N/A
- RXST $22.16
- Revenue Next Year
- MNMD N/A
- RXST $20.91
- P/E Ratio
- MNMD N/A
- RXST N/A
- Revenue Growth
- MNMD N/A
- RXST 46.70
- 52 Week Low
- MNMD $4.70
- RXST $12.53
- 52 Week High
- MNMD $10.44
- RXST $58.23
- Technical
- Relative Strength Index (RSI)
- MNMD 52.28
- RXST 37.82
- Support Level
- MNMD $6.40
- RXST $12.60
- Resistance Level
- MNMD $7.20
- RXST $14.25
- Average True Range (ATR)
- MNMD 0.43
- RXST 0.69
- MACD
- MNMD -0.03
- RXST -0.03
- Stochastic Oscillator
- MNMD 76.03
- RXST 19.74
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.